Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unapproved Device Scheme Lands Marketer With Jail Time, Fines

This article was originally published in The Gray Sheet

Executive Summary

A man was sentenced to 51 months in custody and fined $250,000 following a felony conviction for manufacturing and selling an unapproved cure-all "biofrequency" device, U.S. Attorney Karen Hewitt announced Feb. 12

You may also be interested in...



Hamburg Outlines Planned Reforms Of FDA Criminal Investigations Office

FDA Commissioner Margaret Hamburg outlined reforms planned for the agency's Office of Criminal Investigations, including new criteria for selecting misdemeanor prosecution cases against responsible corporate officials

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

Topics

UsernamePublicRestriction

Register

MT028537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel